Archived

©Bloomberg

Pfizer walks away

Pfizer has admitted defeat in its pursuit of AstraZeneca, bringing an end to a month-long £69.4bn takeover battle that pitted two of the world’s biggest drugmakers against each other

AstraZeneca chair defends Pfizer rebuff

Leif Johansson says he and his board were not intransigent

Comment and analysis

©Bloomberg
Takeover for takeover’s sake calls for a general public-interest test, writes Jonathan Ford
©Bloomberg
Target shareholders are entitled to expect a short ‘virtual bid’ period, writes Adam Bogdanor
Britain’s takeover rules have held up well
– Editorial

Pfizer refuses to rule out tax deals

US drugmaker calls for ‘fundamental reform’

AstraZeneca chief increases stake

Move comes weeks after collapse of Pfizer takeover bid

AstraZeneca to bolster takeover defences

UK group eyes selling revenues rights to help thwart takeovers

Pascal Soriot: Leader of the great escape

The AstraZeneca chief on saying ‘no’ to Pfizer bid

AstraZeneca chief hits back over pay

Share price targets dubbed ‘very crude instrument’

Drug advances key to AstraZeneca defiance

Investors relying on group to come up with blockbusters

UK lesson for Stryker and Pfizer

‘Put up or shut up’ deadline was takeover hurdle for US groups

Pfizer admits defeat in AstraZeneca bid

Month-long battle ends as US pharma group abandons £69.4bn offer

Pfizer revives fears over UK life science

Scaling down of biggest sites points to an industry in transition

AstraZeneca shifts focus to drug pipeline

Clinical data to be showcased at oncology conference

AstraZeneca investors urge Pfizer talks

Large interests want to return to table after cooling-off period

Delaware fears losing AstraZeneca

Locals fret for group’s US base if Pfizer bid succeeds

Astra’s persuasive tale of Britishness

Pharmaceutical group deployed an effective PR campaign

AstraZeneca highlights innovation malaise

Difficulties lie in translating research into commercial products

AstraZeneca deal ‘in injury time’

AstraZeneca battles to shore up support

Shareholder says board ‘acted too hastily’ in rejecting Pfizer

AstraZeneca and Pfizer in war of nerves

US pharma group seeks ways to keep deal prospects alive

Pfizer scrambles to keep Astra bid alive

UK group says no chance of renewed talks leading to increased bid

Pfizer chief’s strategy in spotlight

Ian Read must halt falling revenues and improve drug pipeline

Pfizer / AstraZeneca: more drugs please

Pharma mergers are rarely about promoting innovation

Q&A: Pfizer clarifies bid intentions

US pharma group’s options in its offer for AstraZeneca

Astra investors split on Pfizer rejection

Pfizer snub triggers recrimination at Astra

Shares tumble and investors split on handling of bid

Brinkmanship ends with recriminations

Video conference saw both sides exasperated

AstraZeneca faces task to back up defence

Promise of rich drugs pipeline will be watched with share price

Labour keeps up pressure over Pfizer

Cameron says the government is ‘strictly neutral’

Astra labs must now work miracles

Pfizer leaves door ajar for AstraZeneca board to change its mind

AstraZeneca / Pfizer: the price was right

UK pharma company should have accepted latest offer

Timeline: Pfizer’s approach for Astra

Astra shares tumble as it snubs Pfizer’s bid

Deal faces collapse unless board is forced back to table

AstraZeneca set to reject ‘final’ Pfizer offer

US drugmaker says it will not go hostile if £69bn bid is rebuffed

UK considers options on AstraZeneca bid

US pharma group lines up sweetened bid

Labour threatens to block Pfizer bid

Lawyers say deal might not be completed before 2015 election

SHARE THIS QUOTE